Summer 2017 Newsletter out now

Posted under Fundraising, Newsletter, Research, Research Projects, Supporters on

http://makse.com/?kremel=uniform-dating-android-app&235=bd Our Summer 2017 newsletter is now available to download.  Our biggest ever issue has 16 pages of inspiring fundraising stories, research updates and the exciting news about our new partnership with Oxford-based research Charity, Heads Up. If you have any feedback on the newsletter or would like to be sent a printed copy, please do get […]

Oxford Charity “Heads Up” joins forces with Oracle Cancer Trust

go to the website Oracle Cancer Trust is delighted to announce that the charity is joining forces with Oxford-based head and neck cancer research charity Heads Up Friday 9th June 2017 Heads Up was founded ten years ago with the sole aim of funding research into head and neck cancer.  During this time it has acted as a pathway […]

6th March is European Swallowing Awareness Day

Posted under Fundraising, Patient Care, Research, Supporters on

browse around here Today, 6th March is European Swallowing Awareness Day. Research has shown that up to 60% of patients suffer from swallowing difficulties following treatment for head and neck cancer which is a serious issue as numbers of new cases are increasing at a relentless rate. Oracle Cancer Trust have funded significant research projects to reduce issue […]

Oracle funds new pioneering imaging study

Posted under Research, Research Projects on

mcb forex converter Oracle have pledged funding for an exciting new research project at the Institute of Cancer Research, led by Dr Gabriela Kramer-Marek (pictured) and Oracle Honorary Trustee, Professor Kevin Harrington. The project work, which will take 12 months, will be undertaken by postdoctoral scientist, Dr Carlos Daniel Martins. In his project, Carlos will be investigating how scientists […]

Immunotherapy drug for treating HPV+ head and neck cancers hailed as “game-changer”

Posted under Fundraising, Newsletter, Patient Care, Research, Supporters on

over here A new generation of “game-changing” drugs that harness the body’s immune system have been found to extend the lives of head and neck cancer sufferers.  The drug, Nivolumab, resulted in the doubling of one-year survival rates in clinical trials on HPV+ head and neck cancer patients.  Findings will be presented to the European Society for […]

Oracle-funded study improves treatment prospects for cancer patients

Posted under Newsletter, Patient Care, Research, Supporters on

http://logansquarebeerfestival.com/apple-app-site-association Read the ICR’s latest blog post about the success of our recent Oracle-funded study into combining radiotherapies with viruses to improve treatment prospects for cancer patients. Oracle-funded scientists at the ICR and The Royal Marsden NHS Foundation Trust combined the oncolytic reovirus RT3D, with radiotherapy to treat melanoma, and found that the combination was much […]

New MR Linac Machine taking shape

Posted under Newsletter, Patient Care, Research, Supporters on

New revolutionary radiotherapy machine, thumb MR Linac, salve is taking shape at The Royal Marsden Hospital in Sutton following delivery of a giant magnet. Oracle is funding two PhD students on this pioneering project to study its use with treating head and neck cancer patients. Says Professor Kevin Harrington “Radiation plays a central role in […]

Experimental virus therapy cures Oracle Board Member Sir Michael Lockett

Posted under Fundraising, Newsletter, Patient Care, Research, Supporters on

Sir Michael Lockett took part in a trial under the care of Professor Kevin Harrington using a cold sore virus therapy that cured his head and neck cancer.  Read more in the article that appeared in The Mail on Sunday. http://www.dailymail.co.uk/health/article-3602308/How-cold-sore-virus-killed-cancer-mastermind-London-s-2012-Olympics-reveals-injections-herpes-virus-vaccinated-against-future-tumours.html

New head and neck cancer drug “game changer”

Posted under Fundraising, Newsletter, Patient Care, Research, Supporters on

A new type of cancer drug that wakes up the patient’s own immune system to fight tumours could be a game changer for tackling aggressive head and neck cancers, say experts. The news announced today, 19th April at a conference supports the work of Professor Kevin Harrington.  Read the full news report here.   http://www.bbc.co.uk/news/health-36081336

#UnitingVoices campaign to raise awareness of head and neck cancer

Posted under Fundraising, Patient Care, Research, Supporters on

The European Head and Neck Society have launched a new campaign “Make Sense”.  The campaign aims to raise awareness of the disease through greater education of the signs and symptoms to promote earlier diagnosis and referral, abortion with the ultimate aim of improving patient outcomes. Head and Neck cancer is a preventable disease, rx and […]

Supporter Research Event

Posted under Fundraising, Newsletter, Patient Care, Research, Supporters on

We were delighted to welcome over forty supporters to attend our first Research Innovation Event which was held recently at prestigious The Institute of Cancer Research in London.  The event provided our supporters with an update of current projects as well as our ambitious plans to fund future projects over the next three years. Oracle Chairman […]

Ex-patient Suzie Cooke features in Take a Break

Posted under Fundraising, Research on

Ex-patient Suzie Cooke features in this week’s Take a Break magazine in the health section.  In the article “The cancers we forgot” Suzie talks about how her symptoms were passed off as nothing, and just how little is known about head and neck cancer. Take a Break is the largest read women’s weekly with over […]

Oracle’s Professor Kevin Harrington features on Panorama

Posted under Fundraising, Patient Care, Research, Supporters on

Wednesday 8th February’s episode of Panorama focused entirely on the world of The Institute of Cancer Research in London and The Royal Marsden. Over the past two years the BBC’s Panorama team have been given unprecedented access to the clinical trials and ongoing research at the ICR and The Royal Marsden. Oracle currently funds eight research […]